New publication supports Travera’s technology for predicting optimal treatment for cancer patients

MEDFORD, MASSACHUSETTS – November 2, 2021 – Travera announced today the publication of the results of a study which confirms the potential clinical utility of the company's testing approach to predicting a patient's response to cancer drugs based on subtle changes in the mass of individual tumor cells. The paper, entitled "Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models," published in the journal Cell Reports, is based on a study conducted by researchers from the...

read more

Travera receives CLIA certification for its cancer biomarker testing laboratory

MEDFORD, MASSACHUSETTS – October 26, 2021 – Travera announced today that it has received certification from the U.S. Department of Health and Human Services' Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA) of 1988 for its cancer biomarker testing laboratory in Medford, Massachusetts. The CLIA regulations include federal standards applicable to all U.S. facilities or sites that test human specimens for health assessment or to diagnose, prevent, or treat disease. CMS regulates this testing in...

read more

Travera raises $5.5M Series A Extension led by Khosla Ventures

MEDFORD, MASSACHUSETTS – July 15, 2021 – Travera, Inc. has announced that it has recently closed a $5.5 million Series A Extension. The financing was led by Khosla Ventures and joined by existing investor Horizons Ventures and a new investor in the company, MSA Capital. “We are very pleased to have attracted outstanding new investors, and continue to enjoy the strong support of our existing investors,” stated Clifford Reid, Ph.D., Travera’s CEO. “With this financing we will continue to accelerate the development and validation of our technology, which...

read more

Travera expands testing lab with move to Medford, Massachusetts

MEDFORD, MASSACHUSETTS – January 4, 2021 – Travera, LLC has announced that it has moved from its 1,000 sq.ft. laboratory in Cambridge, Massachusetts to a 3,500 sq.ft. lab in Medford, Massachusetts. This new location remains near the Massachusetts Institute of Technology (MIT), the company's key technology partner. This new, larger lab space will enable Travera to apply for CLIA certification and scale up its production of CLIA certified tests that embody its novel cancer biomarker. About Travera Travera was founded in 2017 to commercialize a...

read more

Travera Awarded Competitive Grant from the National Science Foundation

CAMBRIDGE, MASSACHUSETTS - OCTOBER 8, 2020 – Travera, LLC has been awarded a National Science Foundation (NSF) Phase II Small Business Innovation Research (SBIR) grant in the amount of $1 million to conduct research and development (R&D) of the company's suspended microchannel resonator (SMR) platform for personalized medicine in cancer. This grant will further the company's efforts associated with the previously Phase I SBIR grant the company previously received.  This recently awarded Phase II SBIR grant is intended to help the company further...

read more